(2E,4E,8R,10S,13S,14S,17R,18S,19R)-4-ethyl-13,17-dihydroxy-19-((R)-3-hydroxy-3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoyloxy)-8,10,14,18-tetramethyl-6,15-dioxoicosa-2,4-dienoic acid

ID: ALA3715079

Chembl Id: CHEMBL3715079

PubChem CID: 46236596

Max Phase: Preclinical

Molecular Formula: C34H50O12

Molecular Weight: 650.76

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCC(/C=C/C(=O)O)=C\C(=O)C[C@H](C)C[C@@H](C)CC[C@H](O)[C@H](C)C(=O)C[C@@H](O)[C@H](C)[C@@H](C)OC(=O)C[C@@H](O)C1=C(C)C(=O)OC1=O

Standard InChI:  InChI=1S/C34H50O12/c1-8-24(10-12-30(40)41)15-25(35)14-19(3)13-18(2)9-11-26(36)21(5)28(38)16-27(37)20(4)23(7)45-31(42)17-29(39)32-22(6)33(43)46-34(32)44/h10,12,15,18-21,23,26-27,29,36-37,39H,8-9,11,13-14,16-17H2,1-7H3,(H,40,41)/b12-10+,24-15+/t18-,19+,20+,21-,23+,26-,27+,29+/m0/s1

Standard InChI Key:  QVMDFASEUVGRGL-BDLMUKIXSA-N

Alternative Forms

1. Parent:

   

   ALA3715079

   (2E,4E,8R,10S,13S,14S,17R,18S,19R)-4-ethyl-13,17-dihydroxy-19-[(3R)-3-hydroxy-3-(4-methyl-2,5-dioxofuran-3-yl)propanoyl]oxy-8,10,14,18-tetramethyl-6,15-dioxoicosa-2,4-dienoic acid

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 650.76

Molecular Weight (Monoisotopic): 650.3302

AlogP: 3.40

#Rotatable Bonds: 21

Polar Surface Area: 201.80

Molecular Species: ACID

HBA: 11

HBD: 4

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.54

CX Basic pKa: ┄

CX LogP: 4.47

CX LogD: 1.69

Aromatic Rings: ┄

Heavy Atoms: 46

QED Weighted: 0.06

Np Likeness Score: 1.76

References

1.  (2012)  Tautomycetin and Tautomycetin analog biosynthesis, 

Source

Source(1):

• Patent Bioactivity Data